14:53 EDT UroGen sinks 26% to $7.26 after FDA posts briefing docs for UGN-102
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on URGN:
- Positive Buy Rating for UroGen Pharma Driven by Promising UGN-102 Prospects and Strong Financial Position
- UroGen Pharma Reports Q1 2025 Earnings and Pipeline Progress
- UroGen Pharma’s Earnings Call: Progress and Challenges
- Urogen Pharma’s Promising Developments and High Approval Likelihood: A Buy Recommendation
- UroGen Pharma reports Q1 EPS (92c), consensus (80c)